The widespread availability of glycated haemoglobin measurement has been one of the major advances in diabetes care in the last 20 years. Many different methodologies are available, with different reference ranges and differing reporting protocols. This lack of standardization has limited the value and interpretation of the results, in terms of estimating an individual's risk of complications of diabetes, the setting of service standards, comparative clinical audit and service benchmarking, and clinical research.
The clinical importance of standardizing HbA 1 , or fructosamine) with the risks of long-term complications of diabetes, but they may be clinically helpful in patients with haemoglobin variants. · Laboratories shall participate in an external quality assurance (EQA) scheme which distributes material that closely resembles clinical samples with an appropriate range of HbA 1c concentrations, and which provides comparison data for routine and reference methods that enable standardization efforts to be continuously monitored. · Laboratories shall be able to demonstrate acceptable performance in an accredited EQA programme. · The adoption of the points above will allow harmonization of HbA 1c results in the short-term, so that all results should be directly comparable and analytical performance will be of the standard required for current clinical practice. Further developmental work to allow more rigorous, scienti®c standardization is required, on an international basis.
CLINICAL NEED FOR STANDARDIZATION
The DCCT 1 demonstrated an association between increasing risk of the development of tissue complications of diabetes and higher HbA 1c values in individuals with type 1 diabetes; these ®ndings have been replicated by the UK Prospective Diabetes Study (UKPDS) 2 in type 2 diabetes. Both studies showed a reduction in risk associated with reduction in HbA 1c . In the DCCT, a sustained reduction of HbA 1c from 9´0% to 7´0% over 6´5 years lead to a reduction in the risk of developing retinopathy of 76%, microalbuminuria of 39% and neuropathy of 60%. The risk of developing any microvascular complication of diabetes was reduced by 25% in the UKPDS; HbA 1c was lowered from 7´9% to 7´0% over 10 years by intensive management. HbA 1c assays in the two trials were harmonized through careful comparison procedures. It
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is therefore possible to estimate an individual's risk of developing the tissue complications of diabetes by determining HbA 1c , providing the relationship of the HbA 1c assay to those employed by the DCCT/UKPDS evidence base is known. The ability to compare HbA 1c results from different assays is also important for patient education, standard setting, audit, benchmarking of diabetes services, and to allow implementation of the forthcoming National Health Service Framework for Diabetes.
Currently, in the UK, long-term glycaemic control is assessed by a variety of means: HbA 1c , total glycated haemoglobin, HbA 1 and fructosamine. Following the results of the DCCT and the UKPDS, it is no longer acceptable for persons with diabetes to have their risk of developing renal failure, blindness or peripheral neuropathy assessed by any test other than HbA 1c , because these other tests have no known quantitative relationship to that risk. However, the HbA 1c assays in turn should provide values that can be directly related to the clinical trial evidence base.
ANALYTICAL NEED FOR STANDARDIZATION
HbA 1c is a speci®c form of glycated haemoglobin created by the irreversible binding of glucose to the N-terminus of the haemoglobin b-chain. Current methods for the routine measurement of HbA 1c separate this molecule from its non-glycated form on the basis of differences in either charge, structure or antigenic properties. The most popular techniques of charge-dependent separation (including those used in the UKPDS and DCCT) use ionexchange high-performance liquid chromato-graphy (HPLC). Af®nity chromatography and af®nity HPLC methods utilize the structural changes that follow glycation to identify carbohydrate binding to any site on the haemoglobin molecule (`total glycated haemoglobin'). Immunoassay methods employ monoclonal antibodies that bind speci®cally to HbA 1c . Both the af®nity chromatography and immunoassay methods usually express their results as`HbA 1cequivalent' after calibration to an ion-exchange HPLC instrument.
The use of such different techniques for the measurement of HbA 1c unsurprisingly means that different results can be obtained. However, even techniques that use the same analytical method often report dissimilar values because of the lack of standardization in HbA 1c measurement and the variability in performance between instruments. Harmonization of all HbA 1c methods to the DCCT/UKPDS assays is a ®rst step in bringing true standardization to the test.
Gold standard' reference methods for HbA 1c are being established using mass spectrometry, but these are not intended for routine use. However, in the future they may become important in maintaining traceability to the assays used in the UKPDS and DCCT.
